Estrella Immunopharma, Inc. (ESLA)

NASDAQ: ESLA · Real-Time Price · USD

1.040

-0.060 (-5.45%)

Mar 20, 2026, 4:00 PM EDT - Market closed

Estrella Immunopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2024	FY 2023	FY 2023
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Jun '24 Jun 30, 2024	Dec '23 Dec 31, 2023	Jun '23 Jun 30, 2023
Selling, General & Admin	2.78	3.2	3.2	3.2	0.66
Research & Development	13.05	4.11	4.11	4.11	10.45
Total Operating Expenses	15.83	7.31	7.31	7.31	11.11
Operating Income	-15.83	-7.31	-7.31	-7.31	-11.11
Pretax Income	-15.83	-7.31	-7.31	-7.31	-11.11
Provision for Income Taxes	0	0	0	0	-
Net Income	-15.83	-7.31	-7.31	-7.31	-11.11
Net Income to Common	-15.83	-7.31	-7.31	-7.31	-11.11
Shares Outstanding (Basic)	36	27	27	27	0
Shares Outstanding (Diluted)	36	27	27	27	0
Shares Change (YoY)	34.54%	-0.14%	0.14%	8752.66%	-78.46%
EPS (Basic)	-0.43	-0.25	-0.27	-0.25	-36.35
EPS (Diluted)	-0.43	-0.25	-0.27	-0.25	-36.35
Free Cash Flow	0	-16.07	-16.07	-16.07	-1.34
Free Cash Flow Per Share	-	-0.59	-0.59	-0.59	-4.37
EBITDA	-15.83	-7.31	-7.31	-7.31	-11.11
EBIT	-15.83	-7.31	-7.31	-7.31	-11.11
Effective Tax Rate	-0.01%	-0.02%	-0.02%	-0.02%	0.00%

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q